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Recent progress in lung cancer biology has paved the waytoward great diagnostic and therapeutic potential that
would have been impossible just a few years ago. The steps
that have been made recently underline the great importance
of conjugating the novelties, which derive from basic re-
search, with growing therapeutic requests: the goal is to
achieve the best therapy for the appropriately selected patient.
The role and development of genomics and proteomics, as
well as the importance of gender differences in a pathology
previously considered an exclusive prerogative of man, fall
within this framework.
The Italian Association of Women against Lung Cancer
AIDACP (Associazione Italiana Donne contro il Cancro del
Polmone) was established in 2005 on the initiative of a group
of healthcare professional women (doctors, assistants, nurses,
social workers, etc.) involved in the sector of lung oncology,
who share the problems relative to neoplastic lung pathologyand
who think it is important to put their ideas into practice in an
association that can disseminate information in our country and
transfer the data within the context of programs and social
initiatives of pragmatic intervention.
Over the last few years, AIDACP has been engaged in
informative awareness-raising campaigns concerning this
pathology. Among its objectives, the Association also has
the support of scientific research, linking activities, and
exchange of know-how and information at both the na-
tional and international levels. This Congress, whose pro-
ceedings are published in this supplement of the Journal
of Thoracic Oncology, is the objective result of its scien-
tific and clinical endeavors. Thanks to the precious co-
llaboration of prominent experts in the field, AIDACP
would like to highlight the outstanding aspects that could
change the therapeutic strategies for lung cancer in the
near future.
We would like AIDACP to represent a valid working
tool able to support, both socially and scientifically, a chal-
lenge that cannot be missed.
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